The US is the bigger Cell Based Immunotherapy market: $7 Bn against $1.3 Bn in 2023, about 5.2 times as large.
China grows faster: 24.5% a year, against 21%. The gap still grows from $5.6 Bn to $35 Bn by 2033.
Clinical research: 8,349 active trials in the US, 5,435 in China.
| Measure |  US |  China |
|---|---|---|
| Market size, 2023 | $7 Bn | $1.3 Bn |
| Market size, 2033 projected | $46.9 Bn | $11.9 Bn |
| Growth a year (CAGR) | 21% | 24.5% |
| Money added, 2023–2033 | $39.9 Bn | $10.6 Bn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #2 |
| Market per person, 2023 | $20 | $0.95 |
| Active clinical trials | 8,349 | 5,435 |
| Full report | US report | China report |
Year by year, 2023 to 2033
US China · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Cell Based Immunotherapy, US or China?
The US is the bigger Cell Based Immunotherapy market: $7 Bn against $1.3 Bn in 2023, about 5.2 times as large.
Which grows faster in Cell Based Immunotherapy, US or China?
China grows faster: 24.5% a year, against 21%. The gap still grows from $5.6 Bn to $35 Bn by 2033.
More Cell Based Immunotherapy comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.